Completed PHASE3 INTERVENTIONAL 3-arm NCT01127620

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

A Phase III, Comparative Study for the Efficacy and Safety of Bilastine 20 mg Versus Cetirizine 10 mg and Placebo in the Treatment of Perennial Allergic Rhinitis During 4 Weeks, Followed by a Long-term Safety Extension With Bilastine 20 mg

Sponsor: Faes Farma, S.A.

Conditions Perennial Allergic Rhinitis

Interventions Bilastine Cetirizine Placebo

Updated 5 times since 2017 Last updated: Sep 25, 2012 Started: May 31, 2004 Primary completion: Mar 31, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Perennial Allergic Rhinitis, this trial is completed. The trial is conducted by Faes Farma, S.A. and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Faes Farma, S.A.

Data source: Faes Farma, S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.